巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    SQZ Biotechnologies Company

    SQZ
    3.300
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・SQZ Biotechnologies Company - 延遲價格・最後更新於 10/08 2:58
    最高位
    3.430
    最低位
    3.290
    開市價
    --
    前收市價
    3.300
    成交量(千)
    2.16
    成交額(百萬)
    0.07
    買入
    3.250
    賣出
    3.390
    每手股數
    --
    市值(百萬)
    96.52
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    16.170 - 2.610
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    SQZ Biotechnologies Company
    證券代碼
    SQZ.US
    所屬板塊
    Biotechnology
    公司業務
    SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
    發行量
    28066795
    公司總部
    200 Arsenal Yards Boulevard, Suite 210
    公司網址
    https://www.sqzbiotech.com
    公司電郵
    investors@sqzbiotech.com
    公司電話
    +1 617 758-8672
    暫無內容

    關於

    SQZ Biotechnologies Company(SQZ.US)所屬的行業板塊為Biotechnology。
    SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
    詳細公司背景可參考: https://www.sqzbiotech.com